PARIMATCH
26.6.2020 09:02:04 CEST | Business Wire | Press release
Sergey Portnov, CEO of Parimatch, took to the virtual stage yesterday at Collision at Home – a global virtual conference which brings together tech leaders and high-potential start-ups to discuss the issues affecting the tech industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200626005045/en/
During his speech, Sergey Portnov captivated Collison at Home’s 30,000 strong audience with his experience of transforming Parimatch from a physical bookmaker into a leading international tech and entertainment brand, giving viewers his top five tips on tech transformation.
On transforming into a tech business, Sergey Portnov said:
“At Parimatch we are obsessed with technology. We are a business built by businesspeople with management backgrounds, but now we have taken a major step to becoming a tech business – an endless journey with no destination.
“Tech can either be used as a tool, or can be used to describe a culture, a mindset. Previously at Parimatch, we used tech as a tool, but not anymore. Tech isn’t something which can be outsourced, it has to flow through your DNA. Only once you have this tech culture ingrained in your business will your company start to move ahead.”
Sergey’s top five tips on tech transformation:
Lesson 1 – Accept the sacrifice
“In the journey to tech transformation, you need to accept that you will lose things along the way. You may lose employees, customers, partners, maybe even revenue. Whilst this can be painful, this loss has to be accepted in order to transform and ultimately become stronger.”
Lesson 2 – Hire the best
“Don’t take the easy approach when it comes to hiring talent. We all know that it is people who make (or break) a business. Invest in the best people, and pay them a lot. People should be a serious financial investment. But don’t just pay them well, give them freedom in their role. Motivate them, and give them time to shine.”
Lesson 3 – Speed is of the essence
“For me, tech means speed. Every aspect of a tech business needs to be working at speed. The sports and betting industry are very fast paced, so we are able to surround our brand with that speedy energy. Be audacious and brave, create a culture of speed.”
Lesson 4 – Build company culture
“We are continually working on how to foster loyalty from our existing employees. We work with all of our people and spend time building culture and values. These aren’t just words on paper, we live them and people can see them in our actions. Values need to be authentic, and are essential to building a positive culture, and need to form the backbone of a business.”
Lesson 5 – Balance experience with ambition
“It is important to balance experience with ambition. When one outweighs the other, it causes problems. We were ambitious with little experience once upon a time, we made mistakes and learnt from them. On the other hand, you have businesses with lots of experience but no ambition, they have become complacent and are not likely to last into the future. The ideal balance is 51% ambition and 49% experience.”
A recording of Sergey Portnov’s speech can be viewed here: https://www.youtube.com/watch?v=CQ98g1U-doU&feature=youtu.be
-ENDS-
ABOUT PARIMATCH
Parimatch brings together technology, business and sport to deliver seamless entertainment powered by innovation. Founded in 1994, Parimatch has grown to become one of the largest betting companies in Europe and the CIS, and continues to explore new markets to enter. The business operates with a digital first mindset, and is constantly developing and improving the quality of its customer experience, which is enjoyed in 60 countries across the world. Parimatch’s winning team of brand ambassadors include Conor McGregor, Mike Tyson, Petr Yan and the Shevchenko sisters. Parimatch is also the title sponsor of the popular esports team Virtus.pro, and is the exclusive betting partner to UFC in the CIS region.
ABOUT COLLISION
Collision is “America’s fastest growing tech conference” created by the team behind Web Summit. In five years, Collision has grown from 2,500 to an expected 25,000 attendees from more than 120 countries. Attendees include CEOs of both the world’s fastest growing startups and the world’s largest companies, alongside leading investors and media.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200626005045/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom